Navigation Links
RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece
Date:7/8/2011

therapy has successfully treated over 500 patients.  The typical patient is suffering from congestive heart failure with no treatment options and 3 to 6 months to live.  A half liter of blood is extracted from the patient and sent to the company's subsidiary cell processing facility in Israel.  There the patient's stem cells are extracted and grown from tens of thousands into many millions.  The stem cells are primed for angiogenesis or blood vessel formation.  The patient then travels to a jurisdiction where autologous therapy is permitted and has the stem cells transplanted in a hospital in a catherization laboratory in a procedure similar to angioplasty.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements.  These risk factors include, without limitation (i) our ability to obtain additional financing; (ii) our ability to control our expenses; (iii) our ability through our wholly owned foreign subsidiaries to manufacture and market our stem cell treatments; (iv) our ability to initiate and timely complete clinical trials; (v) the timing of and our ability to obtain and maintain regulatory approvals for our stem cell treatments; (vi) our dependence on the success of our lead stem cell treatment; (vii)
'/>"/>

SOURCE RegenoCELL Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 Virobay, Inc. today announced ... has reached an important milestone, as Virobay has now ... a selective cathepsin S inhibitor.   The ... randomized, placebo-controlled study designed to evaluate the safety, tolerability, ... healthy adults. "The initiation of this Phase ...
(Date:5/23/2013)... , May 23, 2013 Z Trim ... value-added ingredients to a variety of industries, announced that ... a panel discussion at this year,s National Restaurant Association ... 2013, on behalf of the Research Chefs Association.  Chef ... Restaurants: The Good, the Bad and the Ugly," joining ...
(Date:5/23/2013)... EASTON, Mass. , May 23, 2013 ... today announced that the Company will host a teleconference ... to provide a business update. The teleconference information is ... Time: 11:00 a.m. Eastern Daylight Time (EDT) ... ); (302) 607-2001 (Int,l) Passcode: VS22823 ...
(Date:5/23/2013)... BUSAN, South Korea , May 23, 2013 ... collaboration with SillaJen, Inc., a private biotherapeutics and ... of targeted biological products for cancer, announced today ... antibodies in patients treated with the oncolytic and ... This research was published in the ...
Breaking Biology Technology:Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... Partner with Biocareercenter.com ... Oct. 2 According to the National,Postdoc Association, more ... the United States today. With only 30 percent of,this ... emerging need to find more quality jobs in the ...
... Calhoun Credits Early Diagnosis with Saving his Life, ... 2007:,The MedTech Conference will highlight how everyday patients are ... as speakers on the,diversity and strength of the economic ... 1 through Oct. 3., Co-writing "A PASSION TO ...
... MISSISSAUGA, ON, Oct. 2 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: ... the research and,commercial development of technologies targeting the ... its,quarterly results after the close of the North ... conference call and audio web cast will also,be ...
Cached Biology Technology:Bio Career Center Launches First Online Jobs Board for Life Science PhDs, MDs 2U.S. Commerce Secretary Gutierrez to Address AdvaMed 2007 2U.S. Commerce Secretary Gutierrez to Address AdvaMed 2007 3Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 2Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 3Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 4
(Date:5/23/2013)... Public Health at Emory University, along with partners ... a $4 million grant over four years to ... and Exposome Research Center: Understanding Lifetime Exposures). The ... in the United States. , The HERCULES ... Environmental Health Sciences (NIEHS) of the National Institutes ...
(Date:5/23/2013)... cancer patients unnecessarily undergo surgery or harsh treatments ... slow-growing and aggressive forms of the disease. Researchers ... Medical Institutes are developing technology that allows patients ... relatively mild treatments or take drastic measures. , ... an associate professor of biomedical engineering at Case ...
(Date:5/23/2013)... of the world,s largest and fastest growing open-access ... Frontiers in Bioengineering and Biotechnology . ... Frontiers in Bioengineering and Biotechnology will ... emerging bioengineering and biotechnology research to be disseminated ... and Biotechnology will provide an open-science and ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
... the Americas avoid competing for the same lunch, or ... from a new study by a pair of researchers ... shows that it,s not just chance that,s at play, ... force in the evolution of many carnivores, influencing such ...
... 10, 2009)The use of common and readily available screening ... scoring systemssuch as the Framingham Risk Scorehas the potential ... who are not originally thought to be at high ... Society of Interventional Radiology,s 34th Annual Scientific Meeting. About ...
... but scientists have found a Yellowstone National Park alga ... algae called Cyanidioschyzon -- thrives in extremely ... around hot springs, said Tim McDermott, professor in the ... State University. Cyanidioschyzon could someday help ...
Cached Biology News:American carnivores evolved to avoid each other, new study suggests 2Simple test helps predict heart attack risk 2Simple test helps predict heart attack risk 3Montana State team finds Yellowstone alga that detoxifies arsenic 2Montana State team finds Yellowstone alga that detoxifies arsenic 3
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
Normal Bovine Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin lev...
...
Biology Products: